Anaptys Announces Late-Breaking Oral Presentation
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company, announced that complete data from the Phase 2b trial of rosnilimab in rheumatoid arthritis (RA) was accepted for a late-breaking oral presentation at ACR Convergence 2025.
"We are honored to be selected by ACR to present our late-breaking Phase 2b data for rosnilimab in RA," said Paul Lizzul, chief medical officer of Anaptys. "Being selected reinforces the transformational potential of rosnilimab, which delivered a compelling safety and tolerability profile and JAK-like efficacy through six months that was durable for at least three months off-drug.
AnaptysBio will present the data at the American College of Rheumatology (ACR) Convergence 2025 in Chicago, IL.
Author's summary: Anaptys announces oral presentation of rosnilimab data.